Dermatologicals saw limited effects from COVID-19 in Q1 and Q2 2020. There was a small degree of stockpiling in Q1, for example with nappy (diaper) rash treatments as consumers feared a potential shortage, but this was much lower than other categories in consumer health.
Antipruritics shows the second strongest growth in 2020 and is a more significant category of note, as a higher number of consumers are turning to antipruritics to treat the skin of their hands which has become dry and sore from excessive handwashing due to COVID-19. Whilst this segment is also expected to return to more normal historical levels over time, antipruritics is seeing the greatest benefit from COVID-19.
GSK Consumer Healthcare maintains a small lead on Bayer Consumer Care BV in company terms in dermatologicals in 2020. However, in brand terms, Bayer takes top place with its Canesten brand, with GSK’s Lamisil and Zovirax coming in second and third place.
Antipruritics shows the greatest scope for opportunities over the forecast period. Whilst dermatologicals is a mature category and therefore options are more limited for development, the ongoing need for more regular handwashing as a result of COVID-19 is expected to increase the need for such products to ease dry and sore skin.
Pre-COVID-19, there was a swing towards premiumisation in dermatologicals. However, lower consumer disposable incomes as a financial result of the crisis mean this trend has been dampened.
Moving forwards, it is important for players to adapt to meet changing trends and to notice which sub-segments to invest further in, against those which are seeing restrictions. For example, with COVID-19 related personal contact limited, cold sore treatments are likely to see a decline in sales.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Medicated Skin Care industry in Netherlands with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Medicated Skin Care industry in Netherlands, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Medicated Skin Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page